Actionable news
All posts from Actionable news
Actionable news in SPPI: Spectrum Pharmaceuticals, Inc.,

AAAP to be acquired by Novartis; ​Voyager VYGR takes back full rights for Parkinson’s disease program

Price and Volume Movers

Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced that its partner Sanofi Genzyme has opted not to take on development and commercial rights of VY-AADC program for advanced Parkinson’s disease. According to Voyager, Sanofi’s decision was due to the inclusion of rights only outside of the US. As a result, Voyager gains full worldwide development and commercial rights to VY-AADC, which will enter a pivotal Phase 2-3 program later this year. Shares are trading down 12% to $20.00 after hours.

Johnson & Johnson (NYSE:JNJ) announced the FDA approved the 10 mg once-daily dose of XARELTO (rivaroxaban) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy.

Advanced Accelerator Applications S.A. (NASDAQ: AAAP) shares closed up 10% to $18.50 following news Novartis intends to acquire the company for $41 per ordinary share and $82 per ADS, for a total of $3.9b.

Aviragen Therapeutics, Inc. (NASDAQ:AVIR) announced a merger with privately held Vaxart, Inc, with a new ticker or VXRT.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) rose sharply to close up 21% to $23.61. The company received an Outperform rating from Evercore ISI Group and a $85 price target.

Other major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume INCLUDING sub-$1 stocks.



Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE): $1.22; +14%.

Mustang Bio Inc (NASDAQ:MBIO): $9.99; +13%.

Global Blood Therapeutics Inc (NASDAQ:GBT): $38.65; +13%.

Cerecor Inc (NASDAQ:CERC): $1.10; +12%.


Pluristem Therapeutics Inc. (NASDAQ:PSTI): $1.68; -15%.

Achieve Life Sciences Inc (NASDAQ:ACHV): $1.81; -13%.

Proteon Therapeutics Inc (NASDAQ:PRTO): $1.75; -13%.

Fibrocell Science Inc (NASDAQ:FCSC): $2.15; -11%.

Pain Therapeutics, Inc. (NASDAQ:PTIE): $3.47; -10%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst

Rheumatoid arthritis

Phase 3 Phase 3 commencement of enrollment announced October 30, 2017.

Lennox-Gastaut syndrome (LGS)

NDA Filing First Phase 3 trial data released June 2016. Data from second Phase 3 trial also met endpoint - September 2016. NDA submission announced October 30, 2017.

Dravet Syndrome

NDA Filing Top line Phase 3 data released March 2016 met primary endpoint. NDA submission announced October 30, 2017.

XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)

Approved Approval announced October 30, 2017.

Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2

Phase 2 Phase 2 initiation announced October 30, 2017.